Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
Aster
R H
RH
Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53201-2178, USA. richard.aster@bcw.edu
Curtis
B R
BR
Bougie
D W
DW
Dunkley
S
S
Greinacher
A
A
Warkentin
T E
TE
Chong
B H
BH
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D001323:Autoantibodies / Q000097:blood; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects; D010455:Peptides / Q000009:adverse effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000276:immunology; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology*; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab